Research and Markets (http://www.researchandmarkets.com/reports/c90264) has announced the addition of Infections Hepatitis C to their offering.
"Infections Hepatitis C" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each ’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
--Top Companies in early stage Hepatitis C Projects
--Achillion Pharmaceuticals Inc
--Abbott Laboratories
--BioCryst Pharmaceuticals Inc
--AstraZeneca Plc
--Genelabs Technologies Inc
--Biolex Therapeutics
--HanAll Pharmaceutical
--Gilead Sciences Inc
--Innogenetics
--Idenix Pharmaceuticals Inc
--Merck & Co Inc
--Intarcia Therapeutics, Inc.
--Novartis AG
--Nautilus Biotech
--Phenomix Corporation
--Pharmasset, Inc.
--REPLICor Inc.
--Protiva Biotherapeutics Inc
--Vertex Pharmaceuticals Inc
--Roche Holdings Ltd
For more information visit http://www.researchandmarkets.com/reports/c90264
Source: Life Science Analytics
Contacts:
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax:
+353 1 4100 980
